Clinical Trial Update: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) [Phase 3]

View source ↗

Summary

The document reports the completion of a Phase 3 trial evaluating secukinumab versus placebo, in combination with a glucocorticoid taper, for Giant Cell Arterit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Giant Cell Arteritis (GCA) | Phase 3 | Status: COMPLETED